BridgeBio Pharma Inc

BBIO: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
&DLOCK|d^jLOCK|D$^mnYQ

BridgeBio Earnings: Strong Attruby Uptake as Late-Stage Candidates Are Under Regulatory Review

BridgeBio reported $244 million in total revenue in the second quarter, up 120% year over year, of which Attruby contributed $222 million. BridgeBio recorded a net loss of $152 million in the second quarter. Shares were trading flat on Aug. 11.

Sponsor Center